Higher temperatures increased serious hypoglycemia risk for users of certain sulfonylureas but not GLP-1 receptor agonists, while sitagliptin (DPP-4 inhibitor) users had less diabetic ketoacidosis in hotter weather.
~3 million patients analyzedThis massive analysis of Medicaid data found that the relationship between outdoor temperature and diabetes drug safety outcomes varies by specific medication, with sulfonylureas showing heat-related hypoglycemia risk while GLP-1RAs did not.
What the researchers found
Among over 713,000 users of specific diabetes drug classes:
- Higher maximum daily temperatures were linearly associated with increased serious hypoglycemia among users of glimepiride and glyburide (sulfonylureas) but not glipizide (interaction p=0.048)
- An inverse association was found between temperature and DKA among sitagliptin (DPP-4i) users (p=0.016) — less DKA in hotter weather
- Exenatide (GLP-1RA) users showed no significant temperature-DKA association (p=0.080)
- No drug class showed temperature-related changes in sudden cardiac arrest risk
The findings indicate drug-specific and even agent-specific differences in how ambient temperature affects glycemic safety outcomes.
Why it matters
As climate change increases extreme heat events, understanding how temperature interacts with common medications is crucial for patient safety. This is the first large study to examine temperature-drug interactions across multiple diabetes drug classes. The finding that certain sulfonylureas become more dangerous in heat — while GLP-1RAs and DPP-4 inhibitors appear safer — could inform prescribing decisions and heat safety guidelines for vulnerable populations.
How the study worked
Retrospective cohort study linking US Medicaid claims data with Department of Commerce meteorological data across five US states from 1999-2010. Approximately 3 million people with type 2 diabetes were followed at the person-day level. Maximum daily ambient temperature was assigned by residential ZIP code. Modified Poisson regression assessed relationships between temperature and outcomes (serious hypoglycemia, DKA, sudden cardiac arrest) among drug class subcohorts, with effect modification analysis.
What this study cannot tell us
The study used data from 1999-2010, before newer GLP-1RAs (semaglutide, tirzepatide) were available. Exenatide was the only GLP-1RA assessed. The Medicaid population may not represent all diabetes patients. ZIP code-level temperature assignment is imprecise (doesn't account for indoor cooling or individual exposure). The observational design cannot establish causation. Confounders like physical activity, hydration, and adherence in heat may not be fully captured.
How to read the evidence
This is a large retrospective cohort study using linked healthcare and meteorological data. The massive sample size and person-day level analysis provide strong observational evidence, though the historical data (1999-2010) and ecological temperature assignment are limitations.
When this study was published
Published in 2024 using data from 1999-2010. While the data predates newer GLP-1RAs, the methodological approach and findings about temperature-drug interactions remain relevant as climate change intensifies.
The bigger picture
Climate change is increasingly recognized as a health determinant, and people with chronic diseases like diabetes are among the most vulnerable. This study pioneers the investigation of how temperature interacts with specific diabetes medications — a question that will become more urgent as both heat extremes and GLP-1RA use increase. The approach of linking healthcare claims with meteorological data at the person-day level is a methodological innovation applicable to studying other climate-health-medication interactions.
Questions still open
- Do newer GLP-1 receptor agonists like semaglutide and tirzepatide show temperature-related safety patterns?
- What is the biological mechanism by which heat increases hypoglycemia risk with certain sulfonylureas?
- Should prescribing guidelines for diabetes drugs be updated to include heat-related safety warnings?
Common questions
Are GLP-1 drugs safer in hot weather than other diabetes medications?
Why would hot weather affect diabetes drug safety?
Read the original research
Do relationships between ambient temperature and serious adverse health outcomes vary among users of different antidiabetes drugs? A retrospective cohort study of US Medicaid beneficiaries with type 2 diabetes.
BMJ open, 14(10), e085139
Citation
Leonard, Charles E; Bogar, Kacie; Brensinger, Colleen M; Bilker, Warren B; Bell, Michelle L; Flory, James H; Shi, Christopher; Chen, Cheng; Hennessy, Sean. (2024). Do relationships between ambient temperature and serious adverse health outcomes vary among users of different antidiabetes drugs? A retrospective cohort study of US Medicaid beneficiaries with type 2 diabetes.. BMJ open, 14(10), e085139. https://doi.org/10.1136/bmjopen-2024-085139